Drug Trial Radar · NCT07263594
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
127
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Conditions
- Gastrointestinal Cancer
Interventions
DB-1324Drug
Administered I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation and Backfill parts: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.Time frame: Up to safety follow-up visit, approximately 30 days post-treatment
- Dose Escalation and Backfill parts: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to safety follow-up visit, approximately 30 days post-treatment
- Dose Escalation and Backfill parts: Percentage of participants with Treatment Emergent Adverse Events (TEAEs) , Grade ≥ 3 TEAE, TEAE leading to dose reduction/interruption/discontinuationTime frame: Up to safety follow-up visit, approximately 30 days post-treatment
- Dose Escalation and Backfill parts: Maximum Tolerated Dose(MTD) of DB-1324Time frame: Up to safety follow-up visit, approximately 30 days post-treatment
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
USA05-0
Port Saint Lucie, Florida · Recruiting
USA02-0
Grand Rapids, Michigan · Recruiting
USA01-0
Huntersville, North Carolina · Recruiting
USA03-0
Cincinnati, Ohio · Recruiting
AUS02-0
Randwick, New South Wales, Australia · Recruiting
AUS03-0
South Brisbane, Queensland, Australia · Recruiting
AUS01-0
Nedlands, Western Australia, Australia · Recruiting
CHN01-0
Beijing, China · Recruiting
CHN04-0
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.